Water utilities are selling bonds at a record pace to upgrade aging pipes and meet tougher regulations, preparing for a potential pullback in federal funding.
The White House Council of Economic Advisers estimated $529 billion in savings from new drugs sold at most favored nation prices, plus $64.3 billion from applying MFN pricing to Medicaid, totaling over $500 billion over 10 years. However, experts find it difficult to evaluate the estimated nearly $600 billion in savings without more information on the president's current or future policies. Juliette Cubanski, vice president and director of the Program on Medicare Policy at the health policy organization KFF, stated, "Right now we just have a lot more questions than we have answers, and that makes it really difficult to assess the validity or accuracy or even ballpark-ness of this very large estimate of savings in the White House report."
The administration has made voluntary deals with 17 drug companies. The White House and companies have reported commitments to launch new drugs at MFN prices and offer MFN prices to states for Medicaid. However, the details have not been disclosed, and SEC filings indicate some deals last only three years. This raises questions about the long-term impact of these deals and the validity of the $600 billion savings claimed by the Trump administration.
Meanwhile, the Trump administration's claimed drug savings remain largely aspirational, with experts questioning the validity of these estimates and the impact of the voluntary deals with drug companies.
As the potential for a decrease in federal funding looms, water utilities are rushing to sell bonds at a record pace to upgrade aging pipes and meet tougher regulations. This comes as President Donald Trump has touted over $500 billion in prescription drug savings over 10 years from his policies, which have been met with skepticism. The record $21 billion water bonds sold represent a significant policy-driven financial change with implications for infrastructure and the environment.
Trump's administration claims the most favored nation policy will bring down drug prices to levels paid in other countries, saving $529 billion. However, experts find it difficult to evaluate the estimated nearly $600 billion in savings without more information on the president’s current or future policies. Juliette Cubanski, vice president and director of the Program on Medicare Policy at the health policy organization KFF, stated, "Right now we just have a lot more questions than we have answers, and that makes it really difficult to assess the validity or accuracy or even ballpark-ness of this very large estimate of savings in the White House report."
The administration has made voluntary deals with 17 drug companies to lower drug prices. The details of these deals have not been disclosed, and some companies have reported that they end after three years. This raises questions about the long-term impact of these deals and the validity of the $600 billion savings claimed by the Trump administration.
As water utilities prepare for potential budget cuts, the record $21 billion water bonds sold highlight the need for infrastructure and environmental funding. Meanwhile, the Trump administration's claimed drug savings remain largely aspirational, with experts questioning the validity of these estimates and the impact of the voluntary deals with drug companies. The coming months will reveal the true implications of these policy-driven financial changes on infrastructure, healthcare, and the environment.
Highlighted text was flagged by the council. Tap to see feedback.
